Business Context and Reporting Period
Company: Xeris Biopharma Holdings, Inc. (XERS)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024
Overview: Xeris is a commercial-stage biopharmaceutical company focused on chronic endocrine and neurological diseases. Its commercial portfolio includes Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). The company leverages proprietary non-aqueous formulation technologies (XeriSol and XeriJect) for its pipeline, including XP-8121 (once-weekly levothyroxine).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $203.1 million | $163.9 million | +23.9% |
| Net Loss | $(54.8) million | $(62.3) million | -11.9% (Improvement) |
| Operating Loss | $(33.6) million | $(44.0) million | -23.5% (Improvement) |
| Cash & Equivalents | $71.6 million | $67.4 million | N/A |
| Total Debt (Net) | $232.1 million | $190.9 million | +21.6% |
| Accumulated Deficit | $(671.9) million | $(617.0) million | N/A |
Revenue Breakdown:
- Gvoke: $82.8 million (+23.5%)
- Recorlev: $64.3 million (+117.5%)
- Keveyis: $49.5 million (-12.8%)
Liquidity: Net cash used in operating activities was $37.0 million. Net cash provided by financing activities was $36.2 million, primarily driven by $38.2 million in net proceeds from a term loan under an amended credit agreement.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $39.2 million, driven by significant volume and pricing growth in Recorlev and Gvoke, partially offset by a decline in Keveyis due to generic competition.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose by $17.4 million (11.9%), attributed to investments in the Recorlev commercial organization and CEO succession/restructuring costs ($6.1 million). R&D expenses increased by $3.2 million (14.4%) due to higher personnel costs and pipeline spending.
- Debt Refinancing: In March 2024, the company entered into an Amended and Restated Credit Agreement providing $200.0 million in term loans, refinancing prior obligations. This increased total debt but provided liquidity to sustain operations.
- Convertible Notes: As of year-end, $15.2 million of 2025 Convertible Notes and $33.6 million of 2028 Convertible Notes were outstanding.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring net losses for at least the next 12 months. Cash resources are deemed sufficient to sustain operations for at least 12 months from the filing date. The company anticipates continued investment in commercialization of Recorlev, Gvoke, and Keveyis, as well as R&D for pipeline candidates like XP-8121.
Key Risks & Contingencies:
- Profitability: The company has an accumulated deficit of $671.9 million and may never achieve profitability. Additional capital may be required, potentially causing dilution.
- Competition: Keveyis faces competition from generic versions (approved late 2022) and branded generics (Ormalvi launched May 2024). Recorlev and Gvoke face competition from established therapies and new entrants.
- Supply Chain: Reliance on single-source suppliers for key APIs and drug products (e.g., Regis for Recorlev API, Lonza for Recorlev drug product, Taro for Keveyis) creates supply risk.
- Regulatory: Risks include FDA approval delays for pipeline candidates, potential withdrawal of approvals, and compliance with healthcare fraud and abuse laws.
- Intellectual Property: Keveyis lost orphan drug exclusivity in August 2022; the company is appealing patent applications to restore exclusive rights.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $71.6 million cash balance against projected burn rates, given the expectation of continued net losses.
- Debt Covenants: Review the terms of the Amended and Restated Credit Agreement, specifically covenants restricting dividends, additional indebtedness, and the maturity dates tied to the Convertible Notes.
- Keveyis Revenue Trajectory: Monitor the impact of generic competition on Keveyis sales, which declined 12.8% in 2024.
- Recorlev Growth Sustainability: Assess whether the 117.5% revenue growth in Recorlev is sustainable as the product matures and competition increases.
- Pipeline Progress: Track the status of XP-8121 (once-weekly levothyroxine) Phase 3 trial initiation and FDA interactions.
- Convertible Note Conversion: Evaluate the potential dilution impact if the $48.8 million in outstanding Convertible Notes are converted into equity.